Intercellular signaling sits at the center of this dementia and brain health question.

Recent scientific discoveries suggest that new Alzheimer’s treatments may emerge from a surprising direction: restoring broken communication between brain cells. Researchers have identified that in Alzheimer’s disease, neurons lose their ability to signal to one another effectively—a problem driven by dysregulated signals involving proteins encoded by CALM and APOE genes. When these intercellular communication pathways fail, both excitatory and inhibitory neurons show dramatic decreases in the quantity and strength of their signals. This discovery matters because targeting these communication failures offers a fundamentally different approach than earlier drug development efforts that focused primarily on clearing amyloid plaques alone.

The implications are already moving into clinical practice. Two new tau-targeting antibody drugs—BMS-986446 from Bristol Myers Squibb and etalanetug from Eisai—received FDA fast-track regulatory designation in late 2024 and are currently in Phase 2 clinical trials expected to conclude within the next two years. Beyond these near-term candidates, researchers are also exploring therapies that address microglia inflammation, improve blood-brain barrier transport, and remove specific enzymes from neurons to reduce amyloid accumulation. This article examines what intercellular signaling disruption means for Alzheimer’s patients, explores the specific mechanisms behind these emerging treatments, and explains why these discoveries represent a meaningful shift in how the field approaches this disease.

How Does Intercellular Signaling Fail in Alzheimer’s Disease?
Understanding the Tau Protein Connection to Communication Breakdown
The Microglia Inflammation Pathway and Toxic Lipid Production
Multiple Therapeutic Pathways Show Promise in Different Ways
The Challenge of Blood-Brain Barrier Access and Delivery
Reducing Amyloid Through Neuronal Enzyme Removal
The Future of Intercellular Signaling-Based Therapies
Conclusion

How Does Intercellular Signaling Fail in Alzheimer’s Disease?

Intercellular signaling is the brain’s chemical language—the way neurons communicate with one another to process information, form memories, and regulate all cognitive functions. In a healthy brain, neurons release neurotransmitters and other signaling molecules that bind to receptors on neighboring cells, creating coordinated networks of activity. In Alzheimer’s disease, this communication system breaks down. research using single-cell and spatial transcriptomics has revealed that the ligands encoded by CALM and APOE genes—which are critical for maintaining these signals—become dysregulated, meaning neurons produce either too much or too little of these signaling molecules.

What makes this disruption particularly damaging is that it affects both types of neurons in ways that destabilize the brain’s chemical balance. Excitatory neurons, which normally activate other neurons, produce weaker and fewer signals. Inhibitory neurons, which normally restrain excessive activity, also show decreases in signal strength and quantity. This dual disruption is comparable to an orchestra where some musicians are playing too quietly while the conductor’s instructions are also becoming inaudible—the result is that the whole system loses coordination. The changes to glutamatergic transmission (signals involving the neurotransmitter glutamate) and Netrin signaling occur as direct consequences of tau protein hyperphosphorylation and the aging process itself, meaning these communication breakdowns are intimately linked to the tau tangles and cellular stress that define Alzheimer’s pathology.

How Does Intercellular Signaling Fail in Alzheimer's Disease?

Understanding the Tau Protein Connection to Communication Breakdown

Tau is a protein that normally stabilizes the structural scaffolding inside neurons, but in Alzheimer’s disease, it becomes hyperphosphorylated—acquiring extra phosphate groups that cause it to misfold and aggregate into toxic tangles. This misfolded tau doesn’t just damage the cell’s internal structure; it also interferes with the molecular machinery that produces and releases neurotransmitters. When tau becomes hyperphosphorylated, neurons struggle to manufacture and transport the signaling molecules needed to communicate with their neighbors. This mechanism explains why tau-targeting drugs like BMS-986446 and etalanetug received FDA fast-track designation: if researchers can stop tau from becoming hyperphosphorylated or clear misfolded tau before it spreads, they can potentially restore the neuron’s ability to produce normal quantities of signaling molecules.

However, a critical limitation exists with tau-targeting drugs alone: they typically work best when tau tangles are already forming but before they have caused irreversible neuronal death. Once neurons have died or been severely damaged, even clearing tau cannot restore lost cells. This timing challenge is why clinical trials for these drugs focus on patients with early cognitive impairment or mild dementia rather than advanced cases. The Phase 2 trials currently underway will determine not only whether these drugs reduce tau pathology, but whether that reduction actually slows cognitive decline in ways patients can notice. The timeline matters for patients and families: if successful, results from these trials should be available within two years, potentially leading to regulatory approval and wider availability by the late 2020s.

The Microglia Inflammation Pathway and Toxic Lipid Production

Beyond tau tangles and amyloid plaques, Alzheimer’s disease involves chronic brain inflammation driven largely by microglia—specialized immune cells in the brain. Recent research has identified that activation of the integrated stress response (ISR) pathway in microglia triggers these cells to produce and release toxic lipids that contribute to neuronal damage and synaptic loss. This discovery opened an entirely new therapeutic avenue: instead of only targeting amyloid or tau, researchers can now work to prevent microglia from becoming overly activated and producing these harmful lipids.

In mouse models of Alzheimer’s disease, inhibiting ISR activation or blocking the enzymes that synthesize these toxic lipids prevented both synapse loss and tau protein accumulation. This is significant because it shows that reducing neuroinflammation can have cascading benefits—it not only protects synapses from immediate damage but also appears to slow tau pathology itself. The comparison here is important: while tau-targeting drugs address one aspect of the disease, anti-inflammatory approaches address the brain’s reaction to disease, offering a complementary rather than competing strategy. A limitation, however, is that most of these anti-inflammatory therapies remain in preclinical development in animal models; human trials are still in early stages or have not yet begun.

The Microglia Inflammation Pathway and Toxic Lipid Production

Multiple Therapeutic Pathways Show Promise in Different Ways

The field is currently pursuing several distinct approaches to restore intercellular signaling, each targeting different points in the disease process. Tau-targeting antibodies (like the two drugs in Phase 2 trials) work by clearing misfolded tau before it can spread and damage communication networks. Microglia-targeted therapies work by reducing neuroinflammation and preventing toxic lipid release. Blood-brain barrier transport strategies using LRP1-targeted polymersomes work by improving the brain’s ability to clear amyloid-beta through receptor-mediated transport. And enzyme removal approaches work by boosting receptors for APOE and increasing amyloid-beta regulation within neurons themselves.

This multi-pathway approach reflects an important shift in thinking: Alzheimer’s disease is not one problem with one solution, but rather a complex cascade of interconnected failures that may require multiple treatments working in concert. For patients and caregivers, this creates both opportunity and complexity. The opportunity is that if one approach shows benefit, combinations might show even greater benefit. The complexity is that future Alzheimer’s treatment may require taking multiple drugs simultaneously, each targeting a different aspect of the disease. Current clinical development efforts are beginning to explore these combination approaches, though results are still preliminary. The tradeoff is clear: greater complexity in treatment, but potentially much greater effectiveness if the science bears out.

The Challenge of Blood-Brain Barrier Access and Delivery

One of the most persistent challenges in Alzheimer’s drug development is the blood-brain barrier—a highly selective filter that prevents many substances from passing from the bloodstream into the brain. Most large drug molecules, including antibodies like BMS-986446 and etalanetug, have difficulty crossing this barrier efficiently. Researchers have developed novel LRP1-targeted polymersomes that attach to specific receptors on blood-brain barrier cells, using the brain’s own transport mechanisms to ferry therapeutic molecules across this protective wall.

However, even with improved delivery technologies, getting sufficient concentrations of a drug to all affected regions of the brain remains challenging. Different areas of the brain are affected at different rates and to different degrees in Alzheimer’s disease, so a drug might work well in one region but not penetrate adequately into another. This is why imaging studies during clinical trials are so important—they help determine whether a drug is actually reaching its target sites in the brain. For patients considering enrollment in early-stage clinical trials, this limitation means that a drug’s failure to show benefit in a trial might reflect delivery problems rather than ineffectiveness of the therapeutic approach itself.

The Challenge of Blood-Brain Barrier Access and Delivery

Reducing Amyloid Through Neuronal Enzyme Removal

A particularly novel therapeutic approach involves removing a specific enzyme from neurons, which substantially reduces amyloid plaques in preclinical models. This strategy works differently from antibodies that circulate in the bloodstream: instead, it modifies the neurons themselves to better handle and clear amyloid-beta. When researchers removed this enzyme, they observed that receptor levels for APOE and amyloid-beta regulation increased within neurons, essentially giving the cells better tools to manage amyloid accumulation on their own.

This approach could eventually be delivered through gene therapy techniques, allowing a patient’s own neurons to be modified to produce less of this problematic enzyme. A real-world example of this kind of therapeutic thinking is seen in genetic forms of Alzheimer’s disease, where mutations in genes like PSEN1 cause early-onset disease; targeting these specific genetic vulnerabilities has long been a goal of researchers. The enzyme removal approach applies similar logic to the more common sporadic form of Alzheimer’s disease, attempting to identify common enzymatic vulnerabilities that, when corrected, reduce disease burden.

The Future of Intercellular Signaling-Based Therapies

The convergence of these different therapeutic approaches suggests that Alzheimer’s treatment in the next five to ten years will look fundamentally different from current approaches. Rather than relying on a single drug targeting a single pathway, future treatment regimens will likely involve combinations designed to restore intercellular signaling at multiple levels simultaneously: clearing tau tangles, reducing neuroinflammation, improving amyloid clearance, and potentially modifying neurons themselves through gene therapy. The timeline for seeing these advances reach patients depends on ongoing clinical trials.

The tau antibodies in Phase 2 trials represent the nearest near-term option, with potential regulatory approval possible within three to five years if trials show clinical benefit. Later-stage therapies like anti-inflammatory approaches and enzyme-targeting strategies will likely require more time before reaching patients. What makes this moment significant for the field is that researchers now have specific, targetable mechanisms related to intercellular signaling failure, rather than vague notions about “brain inflammation” or “protein misfolding.” This specificity offers hope that future treatments will be more effective than the disease-modifying approaches available today.

Conclusion

The discovery that intercellular signaling disruption is central to Alzheimer’s disease has opened multiple new avenues for treatment development. Recent FDA fast-track designations for two tau-targeting antibodies demonstrate that this science is advancing from laboratory discovery to clinical testing. These drugs are expected to complete Phase 2 trials within the next two years, potentially offering the first treatments specifically designed to address the communication failures between neurons that characterize Alzheimer’s disease.

Beyond the tau antibodies currently in trials, researchers are actively developing therapies targeting microglia inflammation, improving amyloid clearance through novel transport strategies, and modifying neurons to better handle disease pathology. For patients and families currently managing Alzheimer’s disease, the most immediate action is to consult with a neurologist or dementia specialist about eligibility for clinical trials testing these new approaches. For those interested in remaining informed, following updates from major Alzheimer’s research organizations and clinical trial databases will provide real-time information as these promising therapies advance toward potential approval and availability.